GC Biopharma Enhances IVIG Safety Profile with Advanced Prothrombotic Impurity Detection Technology
Proprietary analytical method for precise Factor XI (FXI) measurement published in the Journal of Microbiology and Biotechnology Novel IgG Blocker eliminates heterophilic antibody interference, ensuring clinical-grade purity and mitigating thromboembolic risks Yongin, South Korea, 6th April 2026, ZEX PR WIRE — GC Biopharma (006280.KS), a global leader in plasma-derived protein therapies, today announced......
